Medtronic Launches MiniMed Go MDI System in Europe and Eyes $6.96 B Neurorehab Market by 2035
Medtronic launched the MiniMed Go Smart MDI with Simplera sensor in Europe, integrating InPen pen sensor data into one app for patients aged seven and older. The neurorehabilitation market, valued at $2.46 billion in 2025, is forecast to reach $6.96 billion by 2035 at 10.95% CAGR, enhancing Medtronic’s growth outlook.
1. MiniMed Go Smart MDI Launch in Europe
Medtronic has begun rolling out the MiniMed Go Smart MDI system with Simplera sensor across key European markets. The system consolidates insulin dose data from the InPen smart pen and continuous glucose readings into a unified mobile app for users aged seven and older.
2. Planned Separation of Diabetes Business
The company’s diabetes business, to operate under the MiniMed name, remains on track for separation by the end of 2026. Medtronic filed its S-1 in December 2025 for a proposed IPO, aiming to issue new common stock followed by a split-off.
3. U.S. Regulatory Milestones for MiniMed 780G
In February, Medtronic secured FDA clearance for the MiniMed 780G system with ultra-rapid-acting insulins Fiasp and Lyumjev and expanded Medicare coverage for pairing with Abbott’s Instinct sensor. The 780G platform also gained clearance for insulin-requiring type 2 diabetes use with the Instinct sensor.
4. Neurorehabilitation Market Growth Outlook
The global neurorehabilitation devices market is estimated at $2.46 billion in 2025 and is projected to grow at a 10.95% CAGR to $6.96 billion by 2035. This expansion presents significant opportunity for Medtronic’s neurostimulation and rehabilitation product lines.